Can we predict apixaban levels in asian hearts?
NCT ID NCT07747948
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This observational study looks at how the blood thinner apixaban is processed in the bodies of Asian patients with atrial fibrillation. Researchers will analyze existing medical records and blood concentration data from about 200 patients to understand how factors like kidney function and body weight affect drug levels. The goal is to identify what influences apixaban clearance and distribution, which could help personalize dosing in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Apixaban (oral tablet, 2.5 mg or 5 mg twice daily)
- What this could lead to
- If successful, this could help doctors tailor apixaban dosing for Asian patients with atrial fibrillation, potentially improving safety and effectiveness.
- What could go wrong
- This is an observational study using existing data, so it cannot prove cause and effect. Results may not apply to all patients, and the analysis depends on the quality of the collected records.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON VALVULAR ATRIAL FIBRILLATION (NV AF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Faculty of Medicine, Chulalongkorn University
Pathum Wan, Bangkok, 10330, Thailand